The Danish drugmaker filed for a preliminary injunction in New Jersey federal court, arguing Lilly’s Mounjaro ads compare against an outdated, lower Ozempic dose while ignoring the higher dose the FDA approved more than four years ago
Newsflash:
The new autoinjector delivers an IV-equivalent 80 mg furosemide dose at home, and MannKind paired the approval …
The Danish drugmaker filed for a preliminary injunction in New Jersey federal court, arguing Lilly’s Mounjaro ads compare against an outdated, lower Ozempic dose while ignoring the higher dose the FDA approved more than four years ago
The new autoinjector delivers an IV-equivalent 80 mg furosemide dose at home, and MannKind paired the approval …
The Danish drugmaker filed for a preliminary injunction in New Jersey federal court, arguing Lilly’s Mounjaro ads compare against an outdated, lower Ozempic dose while ignoring the higher dose the FDA approved more than four years ago
The new autoinjector delivers an IV-equivalent 80 mg furosemide dose at home, and MannKind paired the approval …
LEADERS
INVESTMENTS
INNOVATION
PARTNERSHIPS
In-Depth Analysis
In-Depth Analysis
Explore our longform features and deep dives into biotech breakthroughs and innovation.
Expert Opinions
Expert Opinions
Read opinions and commentary from leading scientists, investors, and pharma leaders.
Funding & IPOs
Funding & IPOs
Track the latest funding rounds, IPO announcements, and investment trends in biotech/pharma.
Clinical Results & Milestones
Clinical Results & Milestones
Stay informed on pivotal trial results, FDA approvals, and key clinical milestones.
1
2
3
4
5
6
7
8
9
10
1
2
3
4
5
6
7
8
9
10
The Reporter Newsletter
Expert picks and exclusive deals, in your inbox.
A new market report projects 8.6 percent annual growth through 2031, driven by cell and gene therapy pipelines, precision medicine, and sponsors seeking flexible capacity outside their home markets
A new market report projects 8.6 percent annual growth through 2031, driven by cell and gene therapy pipelines, precision medicine, and sponsors seeking flexible capacity outside their home markets
Watch Now
Depot blast in Bangladesh kills nearly 50 people - BBC News
Russia accused of stealing about 600,000 tonnes of Ukraine's grain - BBC News
Devastation of Australia's climate change crisis captured on camera - BBC News
Boris Johnson survives leadership vote but 41% of his MPs have “no confidence” - BBC News
The Danish drugmaker filed for a preliminary injunction in New Jersey federal court, arguing Lilly’s Mounjaro ads compare against an …
Starting July 31, large drugmakers face a 100 percent duty on patented medicines and active ingredients unless they secure onshoring …
Listen Now
Starting July 31, large drugmakers face a 100 percent duty on patented medicines and active ingredients unless they secure onshoring or pricing deals with the Trump administration, and the ripple effects are already reaching contract manufacturers and clinical trial sponsors worldwide
The Danish drugmaker filed for a preliminary injunction in New Jersey federal court, arguing Lilly’s Mounjaro ads compare against an outdated, lower Ozempic dose while ignoring the higher dose the FDA approved more than four years ago
The new autoinjector delivers an IV-equivalent 80 mg furosemide dose at home, and MannKind paired the approval with a $50 million private placement to fund launch
December 18 brings a milestone for cell therapy in graft-versus-host disease—and a setback for Duchenne muscular dystrophy research, highlighting the regulatory tightrope in advanced therapeutics.
Ready To Explore Industry News?
All articles are free -no payment or registration required.
Already a subscriber?